Indobufen versus aspirin in patients with indication for antiplatelet therapy: A systematic review and meta-analysis
Vascular Pharmacology · 2025-03 · 158 · 107465
DOI: 10.1016/j.vph.2025.107465 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Vascular Pharmacology, 2025-03. Verfasst von Deivyd Vieira Silva Cavalcante und 6 weiteren Autor:innen. Beteiligte Einrichtung: Federal University of Maranhao, São Luís, Brazil. Electronic address: deivyd@phdfoc.us. Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors, Aspirin, Myocardial Infarction, Cyclooxygenase Inhibitors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Aspirin is commonly recommended for individuals who have experienced stroke or myocardial infarction (MI). Indobufen, a cyclooxygenase-1 inhibitor, has been studied as a potential alternative. We conducted a meta-analysis and trial sequential analysis (TSA) to compare indobufen with aspirin in patients requiring antiplatelet therapy. METHODS: We searched PubMed, Scopus, and Cochrane Central for studies that compared indobufen and aspirin antiplatelet therapies. We focused on efficacy outcomes, such as composite vascular events, MI, and ischemic stroke, and safety outcomes, such as major bleeding and any bleeding. Heterogeneity was assessed using I2 statistics, and our analysis followed the PRISMA guidelines. RESULTS: The review included 5 studies with 11,943 patients (indobufen n = 5952, 49.84 %), three involving post-MI and two involving post-stroke patients. No significant differences were found between the groups in composite vascular events at 90 days (RR 0.84; 95 % CI 0.46-1.53; p = 0.560; I2 = 53 %) and 1-year (RR 1.13; 95 % CI 0.99-1.29; p = 0.08; I2 = 0 %). MI (RR 0.73; 95 % CI 0.43-1.22; p = 0.22; I2 = 0 %), ischemic stroke (RR 1.16; 95 % CI 0.99-1.37; p = 0.06; I2 = 0 %), and cardiovascular death (RR 1.35; 95 % CI 0.80-2.26; p = 0.257; I2 = 0 %) at 1-year also showed no significant differences. Major bleeding at 1 year (RR 0.73; 95 % CI 0.41-1.31; p = 0.297; I2 = 64 %) was comparable, but any bleeding at 1 year showed a significant difference (RR 0.65; 95 % CI 0.43-0.98; p = 0.03; I2 = 87 %) favoring indobufen. Subgroup analysis of RCTs showed marginally significant increased risk regarding ischemic stroke with indobufen (RR 1.18; 95 % CI 1.00-1.39; p = 0.05). CONCLUSION: The efficacy and safety of antiplatelet therapy with indobufen were comparable to those of aspirin alone. Therefore, indobufen can be considered as a suitable alternative for patients who are intolerant or hypersensitive to aspirin. Nevertheless, additional trials involving larger populations are required to establish their clinical applicability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Federal University of Maranhao, São Luís, Brazil. Electronic address: deivyd@phdfoc.us.
- Medical College Thiruvananthapuram, Kerala, India.
- City University of São Paulo, Sao Paulo, Brazil.
- Christus University Center, Fortaleza, Brazil.
- Federal University of Bahia, Salvador, Brazil.
- INC Hospital, Curitiba, Brazil; Faculdades Pequeno Príncipe, Curitiba, Brazil; Irmandade da Santa Casa de Misericórdia de Curitiba, Curitiba, Brazil. Electronic address: wiltonfg@cardiol.br.
Zitieren
APA
Cavalcante, D. V. S., Krishna, M. M., Joseph, M., de Farias Santos, A. C. F., Mendes, B. X., Asbeg, N., & Gomes, W. F. (2025). Indobufen versus aspirin in patients with indication for antiplatelet therapy: A systematic review and meta-analysis. Vascular Pharmacology, 158, 107465. https://doi.org/10.1016/j.vph.2025.107465
Vancouver
Cavalcante DVS, Krishna MM, Joseph M, de Farias Santos ACF, Mendes BX, Asbeg N, et al. Indobufen versus aspirin in patients with indication for antiplatelet therapy: A systematic review and meta-analysis. Vascular Pharmacology. 2025;158:107465. doi:10.1016/j.vph.2025.107465
BibTeX
@article{Cavalcante2025,
author = {Cavalcante, Deivyd Vieira Silva and Krishna, Mrinal Murali and Joseph, Meghna and de Farias Santos, Ana Clara Felix and Mendes, Beatriz Ximenes and Asbeg, Nicole and Gomes, Wilton Francisco},
title = {Indobufen versus aspirin in patients with indication for antiplatelet therapy: A systematic review and meta-analysis},
journal = {Vascular Pharmacology},
year = {2025},
volume = {158},
pages = {107465},
doi = {10.1016/j.vph.2025.107465}
}
EUVIMED